The management of the residual mass in the retroperitoneum following induction chemotherapy for metastatic testicular cancer has evolved over the past three decades. A multidisciplinary approach involving cisplatin-based chemotherapy and postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) has increased long-term survival rates above 80%. Advances into the appropriate patient selection and timing of surgery have lowered morbidity while improving oncologic outcomes. However, areas of controversy still exist within the field. Management of the small residual mass, predictors of the histology of the residual mass, the extent of PC-RPLND, the role of PC-RPLND in the setting of elevated serum tumor markers, and the role of positron-emission tomography are all topics of ongoing research and debate. We will discuss these issues and review the current guidelines for the management of the residual postchemotherapy retroperitoneal mass in this review.
Introduction
Advances in the medical and surgical approaches to testis cancer over the past 30 years have decreased the mortality of patients with metastatic germ cell tumors from over 50% to less than 20% [Carver et al. 2007a ]. The development of effective cisplatin-based chemotherapeutic regimens, improvements in radiographic imaging technology and advances in the surgical technique of the retroperitoneal lymph node dissection (RPLND) have all been instrumental in this improvement. Of equal importance is the evolution of the appropriate timing of surgery and chemotherapy to maximize oncologic efficacy while minimizing patient morbidity. As such, the current treatment paradigm for testis cancer represents the model for the multidisciplinary treatment of a solid neoplasm. This article will focus on the management of residual retroperitoneal masses following chemotherapy for germ cell tumors. Nonseminomatous germ cell tumors (NSGCT) and pure seminomatous germ cell tumors will be discussed separately, as their management is different.
Nonseminomatous postchemotherapy residual retroperitoneal masses
At diagnosis, the National Cancer Center Network (NCCN) and European Germ Cell Cancer Consortium Group (EGCCCG) guidelines recommend induction chemotherapy for stage IIC or higher retroperitoneal (RP) masses in both seminomatous and NSGCT . Following completion of chemotherapy, 70% of men experience a complete response, defined as normalization of serum tumor markers and radiographic resolution of the RP mass [Donohue et al. 1998 ]. (We will limit the first part of our review to patients with a complete response to chemotherapy and discuss PC-RPLND in patients with elevated tumor markers separately.) The remaining 30% of men have a residual RP mass that could be one of four pathological entities: necrosis/fibrosis, teratoma, residual germ cell tumors (GCT), or non-germ cell carcinoma (usually malignant transformation of teratoma). The frequencies of these histologies vary in the literature and are changing with the evolution of modern chemotherapy. Averages of the largest series reveal fibrosis/necrosis in 50%, teratoma (including malignant transformation) in 35% and residual GCT in 15% [Sim et al. 2007] . More recent series have demonstrated lower rates of residual GCT (i.e. <10%), likely reflecting improvements in chemotherapy [Carver et al. 2007a ].
The natural history of the various histologies of RP masses if left untreated is quite variable. Complete fibrosis or necrosis, as its name suggests, is a benign condition that is believed to be of no long-term risk to the patient. Teratoma, while not a malignant lesion, can cause significant morbidity by growing locally and compressing adjacent organs. Since teratoma is resistant to chemotherapy, the only treatment is surgical extirpation [Logothetis et al. 1982; Spiess et al. 2007 ]. In addition, 36% of men undergoing PC-RPLND have a transformation of teratoma into more malignant neoplasms such as sarcoma, adenocarcinoma or primitive neuroectodermal tumor. The rates of this malignant transformation increase to 1218% in the setting of reoperative RPLND or late relapse [Motzer et al. 1998; Carver et al. 2007b] . Transformed teratomas are also often resistant to chemotherapy [Donadio et al. 2003 ]. Finally, residual GCT will inevitably progress and metastasize if not treated.
Predictors of retroperitoneal pathology in non-seminomatous germ cell tumor
While improvements in surgical technique and perioperative care have lowered the morbidity of PC-RPLND, it remains a major abdominal operation with some associated morbidity, requiring a lengthy convalescence. As such, attempts have been made to predict preoperatively which patients will have only necrosis in their retroperitoneum and enable the omission of PC-RPLND.
Initially, Donohue et al. [1987] reported that residual GCT was present in none of 15 patients without teratoma in the orchiectomy specimen, normalization of serum tumor markers and a 90% or greater reduction in the size of the RP mass following chemotherapy. It was suggested that PC-RPLND could be safely omitted in such patients. However, longer institutional follow-up revealed that of the 27 patients meeting these criteria, 26% eventually relapsed. Four of the six relapses occurred in the retroperitoneum [Debono et al. 1997 ].
The predictive ability of the radiographic size of the residual RP mass has been evaluated by several groups. Toner et al. examined the Memorial Sloan-Kettering Cancer Center (MSKCC) experience in 1990, and found that of 39 patients with residual masses smaller than 1.5 cm, three had residual malignancy and five had teratoma [Toner et al. 1990] . A more recent European series was reported in 2003, reflecting a population that received modern chemotherapeutic regimens. In a group of 87 patients who underwent PC-RPLND with a residual mass smaller than 20 mm, 7% had residual GCT and 26% had teratoma. When stratified by size, residual GCT was present in all subgroups, including masses 05 mm [Oldenburg et al. 2003 ]. These findings were confirmed by a recent analysis from MSKCC of a subset of 154 men who had RP masses 1 cm or less (including those with normal postchemotherapy scans). Residual GCT was found in 6% and teratoma in 23% of these patients with minimal or no radiographic evidence of disease [Carver et al. 2006 ].
International
Germ Cell Consensus Classification (IGCCC) risk categories are not predictive of residual GCT at the time of PC-RPLND. Good-, intermediate-and poor-risk patients have the same incidence of residual GCT at around 16%. However, IGCCC categories are predictive of disease-related outcomes and survival [Spiess et al. 2006] . A multivariate logistic model was created in 1995 to predict for necrosis in the residual retroperitoneal mass based on data from 556 patients who underwent PC-RPLND. Variables predictive of necrosis included normal prechemotherapy hCG and alpha-fetoprotein (AFP), elevated prechemotherapy lactate dehydrogenase (LDH), absence of teratoma in the orchiectomy specimen, small size of the prechemotherapy RP mass, and significant reduction in RP mass size following chemotherapy [Steyerberg et al. 1995] . Subsequent attempts were made to validate the model with prospective data. While the overall area under the receiver-operator characteristic curve was reasonably predictive at 0.82, the 20% false-negative rate was considered too high [Steyerberg et al. 1998; Vergouwe et al. 2007 ]. The initial recommendation was to forgo RPLND if the model-predicted probability of necrosis was greater than 70%. However, external validation in 105 good-prognosis NSGCT patients who underwent PC-RPLND revealed that only 4% actually exceeded the 70% threshold, calling into question the clinical utility of the model [Vergouwe et al. 2003 ].
Attempts at predicting the presence of teratoma in the retroperitoneum at the time of PC-RPLND were made from the databases of MSKCC and Indiana University. Teratoma was present in 6786% of the patients with teratoma in the orchiectomy specimen. However, the converse was not true: the absence of teratoma in the orchiectomy specimen was not predictive of its absence in the retroperitoneum. Other predictors of teratoma included yolk sac elements in the testis mass, the volume of the RP mass and the relative change in RP mass size before and after chemotherapy [Beck et al. 2002; Carver et al. 2006 ]. Although these factors may be used to attempt to predict teratoma or benign pathology, none are believed to be accurate enough to forgo PC-RPLND.
Finally, attempts have been made to utilize positron-emission tomography (PET) to metabolically identify residual tumor in the retroperitoneum following chemotherapy. A recent prospective evaluation of 141 patients with residual RP masses undergoing PET prior to PC-RPLND for NSGCT revealed a disappointing 70% sensitivity and 48% specificity in the detection of residual GCT. The poor positive-and negative-predictive values (59% and 51%, respectively) demonstrate the lack of utility of PET in NSGCT [Oechsle et al. 2008] . In addition, teratoma does not demonstrate increased uptake on PET.
Based on the summarized studies, the most recent (2007) EGCCCG guidelines for testis cancer state that no imaging procedures (including PET) nor any prognostic model can reliably predict residual retroperitoneal mass histology. Therefore, in patients with any residual mass and normalization of tumor markers, the residual masses should be resected. The guidelines also state that 'patients who achieve complete remission, that is, normalized tumour markers and no visible residual lesions after chemotherapy, postchemotherapy surgery is not required' ].
This statement is supported by a formal decision analysis based on a consensus panel of expert opinion, but remains controversial [Steyerberg et al. 1999 ]. Examination of long-term outcomes at Indiana University revealed that patients with a 'complete radiographic response' (defined as RP lymph nodes <10 mm) who did not undergo PC-RPLND had identical overall and progression-free survival to those with residual masses who underwent PC-RPLND [Debono et al. 1997 ]. However, the more recent data of Oldenburg and Carver have demonstrated the presence of significant percentages of residual GCT and teratoma in patients with no demonstrable radiographic abnormality [Oldenburg et al. 2003; Carver et al. 2006 ]. It is possible that modern chemotherapy is more effective at achieving radiographic complete responses, despite harboring subclinical residual disease. As such, some centers advocate RPLND in all patients following chemotherapy, regardless of the radiographic completeness of response to chemotherapy.
Oncologic outcomes following PC-RPLND Long-term oncologic outcomes vary depending on the histology of the resected retroperitoneal mass. As previously discussed, complete fibrosis/necrosis has no known long-term clinical significance. Resection of teratoma is essentially curative, however recurrences occur. At 10-year follow-up, 80% of patients with pure teratoma at PC-RPLND remained free from recurrence. Of those with recurrence, 50% had residual GCT, 33% had teratoma and 17% had teratoma with malignant transformation. All but one of these recurrences occurred outside the retroperitoneum, demonstrating the durability of the PC-RPLND in controlling the retroperitoneum with regards to teratoma. Recurrences most commonly occurred in the lungs, retrocrural space and liver [Carver et al. 2007b ].
Resection of residual GCT can also be curative. The original report from Indiana University determined that 70% of patients with complete resection of residual GCT were found to have durable cure, provided they received two cycles of adjuvant chemotherapy. On the other hand, recurrence occurred in all those with completely resected residual GCTs who did not receive adjuvant chemotherapy. Similarly, incomplete resection of residual masses portends a poor prognosis, as 90% recurred [Fox et al. 1993 ]. Thus PC-RPLND confers a therapeutic benefit in many, in addition to the obvious diagnostic benefit, in the management of the residual postchemotherapy mass. Complete resection of residual masses should be considered the standard of care.
Surgical extent of PC-RPLND Another area of controversy involves the anatomic extent of PC-RPLND. Historically, a full bilateral template dissection was performed. All fibroadipose tissue was resected from the crura of the diaphragm to the bifurcation of the both common iliac arteries, and laterally to the medial border of each ureter. Following careful nodemapping studies and improvements in chemotherapy, the superior boundary was lowered to the inferior aspect of the renal veins [Donohue et al. 1982] . Subsequent to this modification, perioperative morbidity was markedly improved, particularly in respect to vascular injury and chylous ascites. More recently, some authors advocate a further limitation in the template in select patients to improve morbidity.
Compared to a primary RPLND, the PC-RPLND is significantly more challenging technically and thus carries higher rates of morbidity. Chemotherapy causes a dense desmoplastic response, causing the mass to be adherent to the great vessels. Bleomycin can cause pulmonary fibrosis, complicating intra-and postoperative fluid management with the risk of pulmonary edema. Additional intraoperative procedures, including nephrectomy, IVC resections, and arterial grafts, occurred in 27% of PC-RPLND in one large series. Major postoperative complications occurred in 20% [Mosharafa et al. 2003 ]. Limiting the template of dissection would theoretically lower these risks. Additionally, modifying the template facilitates nerve-sparing, thus increasing the likelihood of maintaining ejaculatory function.
Modified PC-RPLND templates mirror those in the primary setting. Some variation of the boundaries of dissection exists between institutions, but generally the inferior mesenteric artery is preserved, along with the hypogastric plexus inferior to it and the contralateral iliac nodes. For left-sided tumors, the paracaval, precaval and occasionally interaortocaval node chains are preserved. For right-sided tumors, the paraaortic and preaortic nodes are often preserved.
The first attempt to limit the extent of dissection involved the use of intraoperative frozen section. If the frozen section revealed tumor or teratoma, a full bilateral template was utilized. A modified template was used if the frozen section revealed necrosis. In the first 40 patients approached in this manner, 21 had necrosis on frozen section.
Concordance with the permanent specimen was 86%, with two unrecognized residual tumors and one unrecognized microscopic teratoma. Relapse occurred in 14%, all outside the retroperitoneum [Aprikian et al. 1994 ]. Six-year median follow-up of 62 patients approached this way revealed an 89% concordance with one RP relapse [Herr, 1997] . The authors concluded that limiting the template in this manner was a safe practice.
Two groups have published series reporting the routine use of modified templates without frozen section. Indiana University performed a modified dissection on selected patients with tumor limited to the primary landing zone of the affected testis. Of 100 such patients at a median follow-up of 32 months, four had relapsed. None of these relapses were in the retroperitoneum. The authors stressed the careful selection of these patients, as they represented less than 10% of their PC-RPLND series [Beck et al. 2007b ]. A European group has similar selection criteria, performing modified templates when the mass is less than 5 cm in the primary landing zone. They compared 98 modified templates to 54 full template PC-RPLNDs. One retroperitoneal relapse occurred in a patient with a modified template. However, the complication rate and need for adjunctive surgery was significantly lower in the modified group and the rate of nerve-sparing was higher [Heidenreich et al. 2008a ].
Although nerve-sparing may be facilitated by the use of a modified template, it is also feasible during bilateral full-template PC-RPLND. Up to 79% of highly selected patients treated in this fashion had antegrade ejaculation. With a 98% 5-year relapse-free rate at a median followup of 39 months, nerve sparing did not significantly compromise the oncologic efficacy of the procedure. Right-sided primary tumors and RP mass size greater than 5 cm were negative prognostic factors for the return of antegrade ejaculation on multivariate analysis [Pettus et al. 2009 ].
A recent lymph node mapping study in 532 patients undergoing PC-RPLND revealed the presence of residual GCT or teratoma outside of the modified template in 732%, depending on how a modified template was defined. The highest rate of extra-template disease on a rightsided template was found in the para-and preaortic areas, at 32% and 23%, respectively. For left-sided templates, rates of extra-template disease increased as the boundary of the template approached the left side. Residual disease was found in 29% of interaortocaval specimens, followed by 11% of precaval and 10% of paracaval specimens. The contralateral iliac node package harbored residual disease in 4% in both leftand right-sided primary tumors. The stage at presentation, size of postchemotherapy mass and presence of extra-template mass on imaging were predictive of extra-template disease [Carver et al. 2007c ].
Leaving residual disease in the retroperitoneum will necessitate a 're-do' RPLND, which is an independent risk factor associated with a poor outcome. Patients undergoing re-do RPLND have markedly lower survival rates than comparable patients following standard PC-RPLND [Donohue et al. 1998; Beck et al. 2005] . Considering these poor outcomes in patients with RP relapses following RPLND, modified templates in PC-RPLND should be approached with caution even in well selected patients. Bilateral full-template RPLND remains the gold standard for PC-RPLND.
Salvage and 'desperation' RPLND
Patients with persistently elevated tumor markers following induction chemotherapy are presumed to have residual GCT, regardless of the radiologic response to therapy. They are recommended to undergo salvage chemotherapy regimens, generally consisting of cis-platinum, ifosfamide and either paclitaxel or vinblastine with or without autologous bone marrow transplant . Patients whose tumor markers normalize following salvage chemotherapy have higher rates of GCT in residual retroperitoneal masses when compared to induction chemotherapy. Historically, up to 55% of patients undergoing RPLND following salvage chemotherapy had residual GCT [Fox et al. 1993 ]. However, this rate is decreasing with newer salvage regimens. Investigators at the MSKCC reported their recent experience with RPLND after salvage chemotherapy. Residual GCT was present in only 14% of 36 patients who received taxane-based salvage chemotherapy, compared with 42% of 35 patients who received other second-line chemotherapy. The incidence of teratoma is consistently reported at between 30 and 35% regardless of the type of salvage chemotherapy [Eggener et al. 2007] . Given these high rates of residual GCT, RPLND is recommended for all patients immediately following second-line therapy if serum tumor markers normalize. Adjuvant chemotherapy is not routinely offered when residual GCT is found at RPLND after salvage chemotherapy, as it is considered chemorefractory [Fox et al. 1993; Krege et al. 2008 ].
An uncommon and unique group of patients who have residual RP masses following chemotherapy are those whose serum tumor markers do not normalize after salvage chemotherapy. The prognosis in these patients is poor, as this has been thought to demonstrate disseminated systemic disease. However, there is increasing evidence to support performing RPLND, as some of these patients have locoregional disease alone. RPLND in the setting of elevated tumor markers has been referred to as a 'desperation' RPLND, although some have criticized the pejorative nature of the phrase.
Most patients with persistently elevated markers have residual GCT at desperation RPLND, however teratoma is present in 2040% and necrosis in 1020%. Non-cancer causes of elevated markers should also be considered, including hepatic dysfunction (AFP), marijuana use (hCG) and hypogonadism (hCG) [Beck et al. 2007a ]. It has also been hypothesized that cystic teratoma can cause a slow leak of hCG and AFP into the serum, as fluid aspirated from cystic teratomatous RP masses in patients with elevated serum tumor markers has been demonstrated to have high levels of these markers [Beck et al. 2004] Five-year overall survival following desperation RPLND in one large series was 55%. However, of the patients with residual GCT, 5-year survival was only 34%. Favorable prognostic features were the absence of residual GCT, elevated AFP, lower absolute value of AFP and stable or declining tumor markers. Elevated hCG and rising markers have markedly worse outcomes; patients with rising hCG have such a poor prognosis that they are not recommended to undergo desperation RPLND. Two year survival rates for those with viable GCT in the desperation RPLND specimen are 44% and 17% for those with elevated AFP and hCG, respectively [Beck et al. 2005] . However, in all patients undergoing desperation RPLND, the preoperative predictive value of an elevated hCG and AFP is less clear. In pooled data of 265 patients from seven desperation RPLND series, the likelihood of being without evidence of disease after surgery was 54%, 51% and 48% for patients with elevated AFP, hCG and both, respectively [Beck et al. 2004] . This data suggests that desperation RPLND may be curative in a subset of wellselected patients.
Seminomatous postchemotherapy residual retroperitoneal masses Following induction chemotherapy for stage II or III pure seminoma, approximately 6080% of patients will have residual radiographic disease. Pure seminoma, however, is a distinctly different entity to NSGCT. Teratoma is extremely rare, so concerns about the growing teratoma syndrome and malignant transformation are avoided. Seminoma is associated with greater desmoplasia than NSGCT, especially in the postchemotherapy setting. Residual masses are more intimately involved with the great vessels, often completely obscuring tissue planes. As such, resection of the postchemotherapy seminomatous mass is more technically challenging and is associated with higher morbidity. Often, resection of the residual masses cannot be safely completed, and almost 40% of cases in one series required additional surgeries at the time of resection [Mosharafa et al. 2003 ]. As many as 80% of patients have fibrosis/necrosis in the residual RP mass while the remaining patients have viable seminoma.
Initially, attempts were made to irradiate residual retroperitoneal masses as seminoma is known to be radiosensitive. In the postchemotherapy setting, however, there is no proven benefit over surveillance. A comparison of 70 patients who received RP radiation versus 53 patients who did not found no difference in survival when adjusted for those receiving platinum-based induction chemotherapy. The conclusion of the authors was 'the current recommendation from this series is to not employ adjuvant radiation in any patient' with a residual seminomatous mass [Duchesne et al. 1997 ].
Surgery has been effective in the treatment of seminoma. As of 2004, there were nine prospective studies evaluating patients who underwent surgery or were placed on surveillance following chemotherapy for advanced seminoma. Six were trials evaluating new chemotherapeutic regimens, three were evaluating new imaging technology. Four of the 48 patients who underwent surgery relapsed and none died, giving an 8% relapse rate and a 0% death rate. In comparison, 22 of the 140 patients on surveillance relapsed and eight died from disease or treatment, resulting in a 16% relapse rate and 6% death rate [De Santis et al. 2004] . Given the relatively low incidence of residual seminoma in the RP, low rate of disease relapse on surveillance, and the morbidity of RPLND, appropriate patient selection is crucial if surgery is employed.
Radiographic criteria have been useful in determining which patients will benefit from surgery. Herr et al. [1997] reported that residual seminoma was more likely to be found in patients with well-defined residual masses larger than 3 cm. Six of 13 (46%) of such lesions harbored seminoma, whereas poorly-defined, sheet-like lesions were more likely to be fibrotic. No lesions smaller than 3 cm were found to contain residual seminoma. Further studies have confirmed the 3 cm cutoff: to date, only six lesions smaller than 3 cm containing residual seminoma have been reported. Seminoma was present in 17% of lesions greater than 3 cm in a recent literature review [Heidenreich et al. 2008b ].
Simply applying the 3 cm cutoff and operating on all patients with masses of that size would result in the overtreatment of approximately 80% of such patients. To further reduce this number and more accurately predict the presence of seminoma, PET has been investigated. Following initial reports that showed promise in the predictive ability of PET in seminoma, the SEMPET trial was designed. It is a multicenter prospective analysis of 51 patients with pure seminoma, negative tumor markers, and well-defined RP masses larger than 1 cm following chemotherapy. PET was performed on all patients; 11 underwent resection and 40 went on surveillance. The accuracy of PET was 100% in lesions larger than 3 cm, and 95% in lesions smaller than 3 cm. Overall sensitivity was 80%, with a specificity of 100% [De Santis et al. 2004] . Another study has confirmed the sensitivity of PET, but has questioned its specificity. In 20 patients who underwent PET followed by surgery, three patients had residual cancer while two had sarcoidosis. The patients with sarcoidosis had false-positive PET, reducing the specificity to 47% [Hinz et al. 2008] .
Recent EGCCCG guidelines recommend PET for all patients with residual masses larger than 3 cm, while PET remains optional for those with lesions smaller than 3 cm. A negative PET does not warrant any further intervention, but patients Therapeutic Advances in Urology 1 (4) with a positive PET should be explored surgically to obtain histology. Complete resection of the mass is preferable to biopsy, when possible. Patients with histologically-proven residual disease should receive adjuvant chemotherapy .
Summary
Recent research has clarified some previously ambiguous issues regarding residual postchemotherapy masses. In NSGCT, there is a clear benefit to removing residual GCT or teratoma. All patients with a residual RP mass following chemotherapy should undergo a PC-RPLND. As some patients with a complete radiographic response harbor residual GCT and teratoma, some argue that all patients should undergo PC-RPLND after chemotherapy. The use of modified templates likely reduces intraoperative morbidity, but carries a risk of leaving extratemplate disease unresected. RPLND can offer durable long-term cures in 3050% of patients following salvage chemotherapy or with persistently elevated serum tumor markers. In seminoma, surgery is more difficult and patients should be carefully selected. PET should be performed on all patients with residual masses greater than 3 cm. A positive PET should warrant surgical excision of the mass, while continued surveillance is recommended for patients with negative PET. By following these recommendations, and with continued improvements in chemotherapy and perioperative care, we should be able to improve our oncologic outcomes while decreasing the morbidities of treatment.
computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer. J Urol 137: 1176. Donohue, J.P., Leibovitch, I., Foster, R.S., Baniel, J. and Tognoni, P. (1998) Integration of surgery and systemic therapy: results and principles of integration. Semin Urol Oncol 16: 6571.
Duchesne, G.M., Stenning, S.P., Aass, N., Mead, G.M., Fossa, S.D., Oliver, R.T. et al. (1997) Radiotherapy after chemotherapy for metastatic seminoma: a diminishing role. Eur J Cancer 33: 829835.
Eggener, S.E., Carver, B.S., Loeb, S., Kondagunta, G.V., Bosl, G.J. and Sheinfeld, J. (2007) Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors. Cancer 109: 528535.
